JP2022552314A5 - - Google Patents
Info
- Publication number
- JP2022552314A5 JP2022552314A5 JP2022521958A JP2022521958A JP2022552314A5 JP 2022552314 A5 JP2022552314 A5 JP 2022552314A5 JP 2022521958 A JP2022521958 A JP 2022521958A JP 2022521958 A JP2022521958 A JP 2022521958A JP 2022552314 A5 JP2022552314 A5 JP 2022552314A5
- Authority
- JP
- Japan
- Prior art keywords
- receptor
- cells
- domain
- chimeric antigen
- cd28h
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2025063708A JP7861191B2 (ja) | 2019-10-17 | 2025-04-08 | 免疫のための増強されたキメラ抗原受容体エフェクター細胞操作およびその使用 |
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201962916468P | 2019-10-17 | 2019-10-17 | |
| US62/916,468 | 2019-10-17 | ||
| PCT/US2020/054601 WO2021071962A1 (en) | 2019-10-07 | 2020-10-07 | Enhanced chimeric antigen receptor for immune effector cell engineering and use thereof |
| USPCT/US2020/054601 | 2020-10-07 | ||
| PCT/US2020/056387 WO2021077117A1 (en) | 2019-10-17 | 2020-10-19 | Enhanced chimeric antigen receptor for immune effector cell engineering and use thereof |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2025063708A Division JP7861191B2 (ja) | 2019-10-17 | 2025-04-08 | 免疫のための増強されたキメラ抗原受容体エフェクター細胞操作およびその使用 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2022552314A JP2022552314A (ja) | 2022-12-15 |
| JP2022552314A5 true JP2022552314A5 (cg-RX-API-DMAC10.html) | 2023-10-27 |
| JP7664913B2 JP7664913B2 (ja) | 2025-04-18 |
Family
ID=75537569
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2022521958A Active JP7664913B2 (ja) | 2019-10-17 | 2020-10-19 | 免疫のための増強されたキメラ抗原受容体エフェクター細胞操作およびその使用 |
| JP2025063708A Active JP7861191B2 (ja) | 2019-10-17 | 2025-04-08 | 免疫のための増強されたキメラ抗原受容体エフェクター細胞操作およびその使用 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2025063708A Active JP7861191B2 (ja) | 2019-10-17 | 2025-04-08 | 免疫のための増強されたキメラ抗原受容体エフェクター細胞操作およびその使用 |
Country Status (5)
| Country | Link |
|---|---|
| US (1) | US20240226293A9 (cg-RX-API-DMAC10.html) |
| EP (1) | EP4045539A4 (cg-RX-API-DMAC10.html) |
| JP (2) | JP7664913B2 (cg-RX-API-DMAC10.html) |
| CN (1) | CN114901693A (cg-RX-API-DMAC10.html) |
| WO (1) | WO2021077117A1 (cg-RX-API-DMAC10.html) |
Families Citing this family (16)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US11629340B2 (en) | 2017-03-03 | 2023-04-18 | Obsidian Therapeutics, Inc. | DHFR tunable protein regulation |
| US11459372B2 (en) | 2020-11-30 | 2022-10-04 | Crispr Therapeutics Ag | Gene-edited natural killer cells |
| US11661459B2 (en) | 2020-12-03 | 2023-05-30 | Century Therapeutics, Inc. | Artificial cell death polypeptide for chimeric antigen receptor and uses thereof |
| IL303269A (en) | 2020-12-03 | 2023-07-01 | Century Therapeutics Inc | Genetically engineered cells and uses thereof |
| TW202241935A (zh) | 2020-12-18 | 2022-11-01 | 美商世紀治療股份有限公司 | 具有可調適受體專一性之嵌合抗原受體系統 |
| EP4271798A1 (en) | 2020-12-30 | 2023-11-08 | CRISPR Therapeutics AG | Compositions and methods for differentiating stem cells into nk cells |
| CA3219160A1 (en) * | 2021-05-20 | 2022-11-24 | Robert Kotin | Genomic safe harbors |
| EP4426350A4 (en) * | 2021-11-04 | 2025-09-24 | Artiva Biotherapeutics Inc | Treatment of cancer with nk cells and multispecific engagers |
| US20250018034A1 (en) * | 2021-11-08 | 2025-01-16 | Fate Therapeutics, Inc. | Engineered effector cells and methods of enhancing ubiquitous targeting of solid tumors |
| CN116103239A (zh) * | 2021-11-11 | 2023-05-12 | 南京北恒生物科技有限公司 | 工程化免疫细胞及其用途 |
| CA3247919A1 (en) * | 2022-01-11 | 2023-07-20 | Celularity Inc. | CD16 CLEFT-RESISTANT CONSTRUCTIONS AND THEIR USES |
| KR20250005097A (ko) * | 2022-04-08 | 2025-01-09 | 페이트 세러퓨틱스, 인코포레이티드 | 고형 종양 표적화 골격을 갖는 세포 및 이의 용도 |
| KR20250004622A (ko) | 2022-04-08 | 2025-01-08 | 페이트 세러퓨틱스, 인코포레이티드 | 종양 표적화를 위한 키메라 항원 수용체 |
| WO2024140778A1 (zh) * | 2022-12-27 | 2024-07-04 | 科济生物医药(上海)有限公司 | Nkg2d工程化细胞及其组合物 |
| CN116445414B (zh) * | 2023-03-03 | 2025-07-08 | 广州瑞臻再生医学科技有限公司 | 基因修饰多潜能干细胞衍生的增强型nk细胞的方法及其应用 |
| CN117285651B (zh) * | 2023-09-27 | 2025-06-06 | 中国医学科学院北京协和医院 | 靶向c-MET的嵌合抗原受体、CAR-M及其用途 |
Family Cites Families (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20050113564A1 (en) * | 2003-11-05 | 2005-05-26 | St. Jude Children's Research Hospital | Chimeric receptors with 4-1BB stimulatory signaling domain |
| CN113862292B (zh) * | 2015-01-29 | 2024-12-27 | 明尼苏达大学董事会 | 嵌合抗原受体、组合物以及方法 |
| US12642852B1 (en) * | 2015-11-04 | 2026-06-02 | Fate Therapeutics, Inc. | Genomic engineering of pluripotent cells |
| CN122146606A (zh) * | 2015-11-04 | 2026-06-05 | 菲特治疗公司 | 用于诱导造血细胞分化的方法和组合物 |
| US11578115B2 (en) * | 2017-01-10 | 2023-02-14 | The General Hospital Corporation | Chimeric antigen receptors based on alternative signal 1 domains |
| CN111556892A (zh) * | 2017-12-08 | 2020-08-18 | 菲特治疗公司 | 使用增强的iPSC衍生的效应细胞的免疫疗法 |
| BR112020011017A2 (pt) * | 2017-12-22 | 2020-11-17 | Fate Therapeutics, Inc. | células efetoras imunes intensificadas e uso das mesmas |
| AU2019243315A1 (en) | 2018-03-29 | 2020-09-24 | Fate Therapeutics, Inc. | Engineered immune effector cells and use thereof |
| AU2020437669A1 (en) * | 2020-03-26 | 2022-09-29 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | CD28H domain-containing chimeric antigen receptors and methods of use |
-
2020
- 2020-10-19 EP EP20877752.4A patent/EP4045539A4/en active Pending
- 2020-10-19 CN CN202080090875.9A patent/CN114901693A/zh active Pending
- 2020-10-19 WO PCT/US2020/056387 patent/WO2021077117A1/en not_active Ceased
- 2020-10-19 US US17/769,651 patent/US20240226293A9/en active Pending
- 2020-10-19 JP JP2022521958A patent/JP7664913B2/ja active Active
-
2025
- 2025-04-08 JP JP2025063708A patent/JP7861191B2/ja active Active